House Republicans question FDA’s progress on pharma inspections in India and China

Three of the top Re­pub­li­cans on the House En­er­gy & Com­merce Com­mit­tee on Tues­day sent a let­ter to FDA com­mis­sion­er Rob Califf ques­tion­ing the agency’s progress in ad­dress­ing wor­ri­some phar­ma and API man­u­fac­tur­ing fa­cil­i­ties in In­dia and Chi­na.

The let­ter comes as the FDA has grap­pled with se­vere short­ages of a com­mon can­cer drug thanks to the clo­sure of a site in In­dia. Ear­li­er this month, the agency al­so shift­ed how it’s pri­or­i­tiz­ing phar­ma-re­lat­ed in­spec­tions so that sites in In­dia and Chi­na take prece­dence over US- and EU-based sites, thanks to an up­dat­ed risk-based mod­el cre­at­ed by Con­gress.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN